Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Amgen swallows Micromet to BiTE into ALL market.

Literature DB >> 22491268

Amgen swallows Micromet to BiTE into ALL market.

Cormac Sheridan.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2012 PMID： 22491268 DOI： 10.1038/nbt0412-300c

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

3 in total

1. Engineered T-cell therapy shows efficacy in blood cancer.

Authors: Simon Frantz
Journal: Nat Biotechnol Date: 2011-10-13 Impact factor: 54.908

2. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors: Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544

3. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors: Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal: Blood Date: 2011-08-17 Impact factor: 22.113

3 in total

9 in total

Amgen swallows Micromet to BiTE into ALL market.

1. Engineered T-cell therapy shows efficacy in blood cancer.

2. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

3. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

1. Monoclonal T-cell receptor drugs pique pharma's interest.

2. Branched-linear and agglomerate protein polymers as vaccine platforms.

3. Amgen's bispecific antibody puffs across finish line.

4. Despite slow progress, bispecifics generate buzz.

5. Effect of freezing on recombinant hepatitis E vaccine.

Review 6. Host immune status and response to hepatitis E virus infection.

7. A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.

8. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.

Review 9. Hepatitis E, a vaccine-preventable cause of maternal deaths.